Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Demant rises sharply after double upgrade by BofA
The Demant share climbed about 3.5% today after BofA Securities raised its rating from "Underperform" to "Buy" and increased the price target from DKK 170 to DKK 280. BofA justified the upgrade with stronger market growth in the first quarter, improved demand for the Oticon Zeal product, raised EPS forecasts for 2026 and 2027, and lower capital costs. The revaluation pushed the stock toward the new price target and supports a recovery thesis for Demant. » More on de.investing.com
Demant exceeds Q1 revenue forecast thanks to Oticon Zeal and acquisitions
Demant reports Q1 2026 revenue of USD 6.25 billion, 2.46% above the USD 6.1 billion forecast. Total growth was 16%, driven by 6% organic growth and 10% acquisition-driven growth (mainly from the acquisition of KIND); EPS met expectations. Strong sales in North America and Europe and the launch of Oticon Zeal lifted the gross margin, and the stock rose 0.97% after hours to USD 209.2. Management confirms the 2026 outlook and remains confident about further product launches in the second half of the year. » More on de.investing.com
Demant beats Q1 revenue forecast thanks to hearing-aid growth, stock jumps sharply
Demant reported Q1 2026 revenue of USD 6.25 billion, exceeding the USD 6.1 billion forecast. Drivers were 6% organic growth and roughly 10% acquisition-driven growth following the integration of KIND, as well as the product launch of Oticon Seal, which led to an expansion of gross margin. The stock rose 10.9% to USD 232 after the announcement. Management confirmed the full-year guidance for organic growth of 3–6% and an EBIT range of DKK 4.1–4.5 billion, but cited currency risks and potential market saturation as challenges. » More on de.investing.com
William Demant falls 13% after quarterly results
William Demant reported acquisition-driven revenue growth in Q4 2025, while EBIT before special items fell 10% and free cash flow declined 11%. The takeover of the KIND group increased net debt and pushed the leverage ratio to 3.4, prompting management to suspend share buybacks and prioritize debt reduction. Newly introduced premium hearing aid Oticon Seal is expected to drive growth but failed to reassure investors. For 2026 the company expects organic growth of 3–6% and an EBIT of DKK 4.1–4.5 billion; a return to the leverage target is planned within 18–24 months. » More on de.investing.com
Demant acquires Kind and becomes Germany's largest hearing-aid chain
The Federal Cartel Office has approved the takeover of around 600 Kind branches by the Danish group Demant. Demant is also buying Audifon, the manufacturer owned by Kind, combining about 350 of its own branches in Germany with the acquired locations. The authority considers there to be sufficient competition from other chains, opticians and regional providers despite the merger. The Kind brand name is to be retained, and the previous owning family will withdraw after the transaction is completed. » More on spiegel.de
Historical dividends Dividends
All dividend metrics All metricsIn 2000, Demant has already paid €0.0802 in dividends. The last payout was in May 2000.
Financials
In the last quarter, Demant had revenue of €1.73B and net profit of €158.11M
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 1.73B | - |
| Gross profit | 1.34B | - |
| Net profit | 158.11M | - |
| EBITDA | 413.66M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €10.25B |
Number of shares | 210.9M |
52-week high/low | €49.02 - €25.57 |
| Dividends | No |
Beta | 0.76 |
P/E ratio | 44.72 |
PEG ratio | -1.54 |
P/B ratio | 6.41 |
P/S ratio | 2.93 |
Company profile
Demant A/S, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. It operates in two segments, Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products. The Communications segment provides headsets for collaborative work and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
| Name | Demant |
| CEO | Søren Nielsen |
| Headquarters | Smørum,
ze Denmark |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 05/08/2000 |
| Employees | 26,704 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | WILLF |
Nasdaq Copenhagen | DEMANT.CO |
Copenhagen | DEMANT.CO |
Frankfurt | WDH1.F |
Düsseldorf | WDH1.DU |
London | 0RGT.L |
SIX | WDH.SW |
München | WDH1.MU |
Wien | DEMA.VI |